Page last updated: 2024-10-21

3-nitropropionic acid and Chorea

3-nitropropionic acid has been researched along with Chorea in 2 studies

3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE
3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.

Chorea: Involuntary, forcible, rapid, jerky movements that may be subtle or become confluent, markedly altering normal patterns of movement. Hypotonia and pendular reflexes are often associated. Conditions which feature recurrent or persistent episodes of chorea as a primary manifestation of disease are referred to as CHOREATIC DISORDERS. Chorea is also a frequent manifestation of BASAL GANGLIA DISEASES.

Research Excerpts

ExcerptRelevanceReference
" In the present study we examined whether chronic administration of 3-nitropropionic acid (3-NP), an irreversible inhibitor of succinate dehydrogenase, can replicate the neuropathologic and clinical features of HD in nonhuman primates."1.29Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. ( Beal, MF; Brouillet, E; Dolan, R; Ferrante, RJ; Hantraye, P; Kowall, NW; Leroy-Willig, A, 1995)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brouillet, E1
Hantraye, P1
Ferrante, RJ1
Dolan, R1
Leroy-Willig, A1
Kowall, NW1
Beal, MF1
Palfi, S1
Leventhal, L1
Goetz, CG1
Hantraye, T1
Roitberg, BZ1
Sramek, J1
Emborg, M1
Kordower, JH1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881]Phase 3609 participants (Actual)Interventional2008-03-31Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Behavioral Frequency Score From Baseline to Month 60

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day1.39
B - Placebo1.43

Change in Behavioral Frequency x Severity Score From Baseline to Month 60

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day4.29
B - Placebo5.06

Change in Functional Checklist Score From Baseline to Month 60

"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day-7.93
B - Placebo-8.02

Change in Independence Scale Score From Baseline to Month 60

The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day-26.30
B - Placebo-24.86

Change in Stroop Interference Test - Color Naming From Baseline to Month 60

Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-14.21
B - Placebo-14.51

Change in Stroop Interference Test - Interference From Baseline to Month 60

Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-7.57
B - Placebo-8.61

Change in Stroop Interference Test - Word Reading From Baseline to Month 60

Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-15.25
B - Placebo-19.13

Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60

The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-10.95
B - Placebo-11.36

Change in Total Functional Capacity (TFC) Score From Baseline to Month 60

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-4.53
B - Placebo-4.76

Change in Total Motor Score From Baseline to Month 60

The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day18.06
B - Placebo19.18

Change in Verbal Fluency Test From Baseline to Month 60

The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-5.07
B - Placebo-4.47

Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))

The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventionrank (Mean)
A - Coenzyme Q10 2400 mg/Day303.3
B - Placebo306.7

Number Completing Study at Assigned Dosage Level

(NCT00608881)
Timeframe: 5 years

Interventionparticipants completing study on drug (Number)
A - Coenzyme Q10 2400 mg/Day98
B - Placebo108

Time to a Three-Point Decline in TFC Score or Death

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventiondays to event (Median)
A - Coenzyme Q10 2400 mg/Day917
B - Placebo911

Time to a Two-Point Decline in TFC Score or Death

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventiondays to event (Median)
A - Coenzyme Q10 2400 mg/Day553
B - Placebo549

Other Studies

2 other studies available for 3-nitropropionic acid and Chorea

ArticleYear
Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates.
    Proceedings of the National Academy of Sciences of the United States of America, 1995, Jul-18, Volume: 92, Issue:15

    Topics: Animals; Behavior, Animal; Chorea; Corpus Striatum; Energy Metabolism; Histocytochemistry; Huntingto

1995
Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:3

    Topics: Animals; Basal Ganglia; Brain Mapping; Cebus; Chorea; Dystonia; Mitochondria; Neurotoxins; Nitro Com

2000